title: Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas.
abstract: We evaluated the effects on bone mineral density (BMD) of a 12-month treatment with goserelin depot, a gonadotropin-releasing hormone agonist, in a group of women with symptomatic uterine myomas requiring hysterectomy. Sixteen women, mean age 45.6 +/- 5.0, reporting menorrhagia associated with uterine myomas, candidates for hysterectomy, were scheduled to be treated with goserelin depot for 12 months. BMD was measured at the vertebral (L2-L4) and proximal femur level (femoral neck and trochanter) at the start of therapy and 6, 12, and 18 months later using dual energy X-ray absorptiometry (Hologic QDR 1000/W). The patients were followed for a minimum of 6 months after the end of treatment. Thirteen of the 16 women enrolled completed the treatment and three suspended it after 5, 6, and 7 months, respectively, because of side effects (hot flashes, insomnia, depression). Of the 13 women who completed the treatment, three underwent hysterectomy because of myoma regrowth and the recurrence of symptoms 3-18 months later; four reached the menopause 5-16 months later, and six were all menstruating normally with a follow-up varying from 6 to 18 months. After 12 months of therapy we observed a bone loss at vertebral, femoral neck, and trochanter of 4.4% (P < 0.05 versus baseline; P = not significant versus 6 months), 7.5% (P < 0.01 versus baseline, P < 0.01 versus 6 months), and 7.6% (P < 0.001 versus baseline, P < 0.05 versus 6 months), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, L. Mangiagalli, University of Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bianchi
authors.forename: L
authors.initials: L
authors.lastname: Fedele
authors.forename: M
authors.initials: M
authors.lastname: Vignali
authors.forename: E
authors.initials: E
authors.lastname: Galbiati
authors.forename: R
authors.initials: R
authors.lastname: Cherubini
authors.forename: S
authors.initials: S
authors.lastname: Ortolani
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D003692:Delayed-Action Preparations; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D007889:Leiomyoma / Q000188:drug therapy*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin